Table 2.
lncRNAs in brain and blood samples of PD patients
| lncRNA | Regulation | Cohort composition | Tissue/model | Methods | Reference |
| lincRNA-p21 | ↑ | 20 PD vs 10 controls | Human brain specimens | Real-time PCR validation | [74] |
| MALAT1 | ↑ | ||||
| SNHG1 | ↑ | ||||
| NEAT1 * | ↑ | ||||
| H19 | ↓ | ||||
| MAPT-AS1 | ↓ | 10 PD vs 10 controls | Tissue samples | Real-time PCR validation | [81] |
| SNCA-AS1 | ↓ | 9 PD vs 8 controls | Tissue samples | Real-time PCR validation | [78] |
| AK127687 | |||||
| UCHL1-AS1 | |||||
| PINK1-AS1 | |||||
| AX747125 | |||||
| MAPT-AS1 | |||||
| AL049437 | ↑ | 11 PD vs 14 controls | Tissue samples | Real-time PCR validation | [76] |
| AK021630 | ↓ | ||||
| U1 | ↓ | 3 PD vs 3 controls | Blood leukocytes | Real-time PCR | [82] |
| RP11-462G22.1 | ↓ | ||||
| RP11-462G22.1 | ↑ | 47 PD vs 27 controls | Cerebrospinal fluid | Real-time PCR validation | [51] |
| AC131056.3-001 | ↑ | 72 PD vs 22 controls | Blood leukocytes | Real-time PCR validation | [86] |
| HOTAIRM1 | ↑ | ||||
| lnc-MOK-6:1 | ↑ | ||||
| RF01976.1-201 | ↑ | ||||
| NEAT1* | ↑ | 61 PD vs 42 controls | Peripheral blood mononuclear cells | Real-time PCR validation | [75] |
| linc00302 | ↑ | 50 PD vs 22 controls | Blood leukocytes | Real-time PCR validation | [84] |
| linc00328 | ↑ | ||||
| FAM215A | ↓ | ||||
| MCF2L-AS1 | ↓ | ||||
| NOP14-AS1 | ↓ | ||||
| PART1 | ↓ | ||||
| XIST | ↓ | ||||
| MSTRG.336210.1 | ↑ | 13 controls | Blood exosomes | Real-time PCR validation | [85] |
| lnc-MKRN2-42:1 | ↑ | ||||
| MSTRG.242001.1 | ↑ | ||||
| MSTRG.169261.1 | ↑ | 32 PD |
PD, Parkinson’s disease; *lncRNAs found to be differentially expressed in more than one cohort; ↑ or ↓ symbolize up- or downregulation of lncRNAs expression.